AlphaCentric Advisors
KYMR icon

AlphaCentric Advisors’s Kymera Therapeutics KYMR Stock Holding History

AlphaCentric Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$640K Buy
5,729
+344
+6% +$39.4K 0.57% 51
2026
Q2 		$617K Buy
5,385
+43
+0.8% +$3.7K 0.52% 67
2026
Q1 		$445K Buy
5,342
+307
+6% +$24.3K 0.44% 81
2025
Q4 		$392K Buy
+5,035
New +$340K 0.39% 86

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

AlphaCentric Advisors's KYMR Position: Q3 2026 in Review

AlphaCentric Advisors increased its Kymera Therapeutics (KYMR) stake by 6.4% in Q3 2026, buying an estimated $39.4K and bringing the position to 5,729 shares worth $640K. The position accounts for 0.57% of the portfolio, ranked #51.

AlphaCentric Advisors first reported a position in KYMR in Q4 2025 and has held it in 4 quarters since. 215 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • AlphaCentric Advisors held 5,729 shares of Kymera Therapeutics worth $640K as of Q3 2026.
  • AlphaCentric Advisors bought 344 Kymera Therapeutics shares in Q3 2026, an estimated $39.4K.
  • Kymera Therapeutics made up 0.57% of AlphaCentric Advisors's portfolio in Q3 2026, its #51 holding.
  • AlphaCentric Advisors first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 215 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.